Tyra Biosciences Announces Participation at Upcoming Investor Events

Rhea-AI Summary

Tyra Biosciences (Nasdaq: TYRA) announced management will participate in investor events in November–December 2025, including a hybrid presentation at the Jefferies London Healthcare Conference and one-on-one meetings at the 37th Annual Piper Healthcare Conference.

Jefferies presentation: Wednesday, November 19, 2025 at 4:00 PM GMT (hybrid slides & moderated Q&A) in London, UK; a live webcast will be available on Tyra Biosciences' For Investors page and replayed after the event. Piper conference meetings: December 2–4, 2025 in New York, NY.

News Market Reaction

+0.71%

1 alert

+0.71% News Effect

On the day this news was published, TYRA gained 0.71%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CARLSBAD, Calif., Nov. 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that members of company management will participate in the following investor events:

Jefferies London Healthcare Conference
Format: Hybrid presentation (slides & moderated Q&A) and one-on-one investor meetings
Presentation Date/Time: Wednesday, November 19, 2025, at 4:00 PM GMT
Location: London, UK

37^th Annual Piper Healthcare Conference
Format: One-on-one investor meetings
Date: December 2-4, 2025
Location: New York, NY

A live webcast of the Jefferies event can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.

About Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. TYRA's lead precision medicine stemming from SNÅP, dabogratinib, is a potential first-in-class selective FGFR3 inhibitor. Dabogratinib's current planned clinical development includes BEACH301 for pediatric achondroplasia (ACH), SURF302 for intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC), SURF303 for low-grade upper tract urothelial carcinoma (LG-UTUC) and potentially metastatic urothelial carcinoma (mUC). TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma. TYRA is based in Carlsbad, CA.

For more information about our science, pipeline and people, please visit  www.tyra.bio and engage with us on LinkedIn.

Contact:

Amy Conrad
aconrad@tyra.bio

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-announces-participation-at-upcoming-investor-events-302613236.html

SOURCE Tyra Biosciences

FAQ

When will Tyra Biosciences (TYRA) present at the Jefferies London Healthcare Conference?

Tyra will present on Wednesday, November 19, 2025 at 4:00 PM GMT in a hybrid format with slides and moderated Q&A.

How can investors watch the Tyra (TYRA) Jefferies London presentation live or later?

A live webcast will be available on Tyra Biosciences' For Investors page and will be available for replay after the event.

What format will Tyra Biosciences use at the Jefferies London Healthcare Conference?

The company will use a hybrid presentation including slides plus a moderated Q&A and will also hold one-on-one investor meetings.

When and where will Tyra Biosciences (TYRA) attend the Piper Healthcare Conference?

Tyra management will hold one-on-one investor meetings at the 37th Annual Piper Healthcare Conference in New York, from December 2–4, 2025.

Will Tyra Biosciences (TYRA) offer one-on-one meetings at these events?

Yes. Management will conduct one-on-one investor meetings at both the Jefferies London event and the Piper Healthcare Conference.

Where can investors find details or the webcast for Tyra Biosciences (TYRA) events?

Event details and the Jefferies webcast will be posted on the company's For Investors page on the Tyra Biosciences website.